AG1 (Athletic Greens) Safety, Regulation & Compliance Posture

How the FDA Actually Regulates AG1

Dietary supplements in the United States sit in a regulatory gray zone. The Dietary Supplement Health and Education Act of 1994 (DSHEA) shifted the burden of proof: the FDA does not evaluate safety or efficacy before a supplement reaches store shelves [1]. AG1 falls squarely into this category. The company can market its product without demonstrating clinical efficacy in randomized controlled trials, provided it makes no explicit disease claims.

What the FDA does enforce is current Good Manufacturing Practice (cGMP) under 21 CFR Part 111, which governs identity testing, purity, strength, and composition [2]. AG1 states that its manufacturing partner in New Zealand complies with cGMP. The facility also holds registration with Australia's Therapeutic Goods Administration (TGA), a regulatory body that the World Health Organization recognizes as a "stringent regulatory authority" [3]. TGA registration requires batch-level testing and facility audits that go beyond what the FDA mandates for supplement manufacturers in the U.S.

That distinction matters. A 2022 analysis published in JAMA Network Open tested 57 dietary supplements purchased from major U.S. retailers and found that 12% contained ingredients not listed on the label, while 23% showed measurable deviations from declared potency [4]. Manufacturing in a TGA-audited facility reduces (but does not eliminate) this risk. No system catches everything. The FDA's post-market surveillance relies heavily on adverse event reporting through the MedWatch system [5], which captures an estimated 1% of actual adverse events according to a widely cited HHS Office of Inspector General report.

What NSF for Sport Certification Actually Tests

AG1 carries the NSF Certified for Sport mark. That stamp means something specific, and its limits are worth understanding. NSF International tests for over 270 substances banned by major athletic organizations, including anabolic steroids, stimulants, beta-2 agonists, and diuretics [6]. Each production lot must be submitted for testing, and the manufacturing facility undergoes an annual on-site audit.

The certification does not, however, validate clinical efficacy of the ingredients. It does not confirm that the product "works" for energy, immunity, or gut health. Dr. Pieter Cohen, an associate professor at Harvard Medical School and a leading researcher on supplement safety, has stated: "Third-party certifications like NSF for Sport are useful for confirming a product is free from banned substances, but consumers should not interpret them as evidence of therapeutic benefit" [7]. This is a point often lost in marketing.

NSF for Sport also does not set maximum thresholds for heavy metals below those established by USP or ANSI standards. A product could pass NSF screening while still containing detectable levels of lead, arsenic, cadmium, or mercury within allowable limits. For a single-ingredient product, those limits are rarely a concern. For a 75-ingredient formula like AG1, cumulative exposure from trace amounts across dozens of botanical inputs becomes a more relevant question.

The Heavy-Metal and Contaminant Question

California's Proposition 65 requires products containing chemicals above specific thresholds to carry warnings. AG1 does carry a Prop 65 label for lead. This does not mean the product is dangerous. Prop 65 thresholds are deliberately set well below levels associated with clinical harm. The lead action level is 0.5 micrograms per day, a figure lower than what naturally occurs in many whole foods [8].

Still, the absence of publicly available lot-specific Certificates of Analysis (CoAs) for AG1 is a gap. Brands like Thorne, Momentous, and Ritual publish CoAs or make them available upon request, showing exact measured values for heavy metals in each production batch. AG1 has not matched this level of transparency as of May 2026. The company references internal testing but does not make per-lot data accessible to consumers.

A 2020 study in the International Journal of Environmental Research and Public Health tested 24 commercially available greens powders and found detectable lead in 100% of samples, with concentrations ranging from 0.06 to 1.4 mcg per serving [9]. None exceeded California's Prop 65 threshold for daily exposure. The point is not that greens powders are uniquely risky. The point is that multi-ingredient botanical concentrates carry inherent heavy-metal exposure from soil uptake, and transparent reporting is the standard consumers should demand.

75 Ingredients: What a Large Formula Means for Safety

More ingredients are not inherently better or worse. They are, however, more complex from a pharmacovigilance perspective. AG1 contains adaptogens (ashwagandha, Rhodiola rosea), botanical extracts (milk thistle, grape seed), prebiotics, probiotics, digestive enzymes, and a full multivitamin panel. Each ingredient carries its own safety profile, interaction potential, and dose-response curve.

Ashwagandha (as KSM-66) is included at an undisclosed dose within a proprietary blend. A 2023 pharmacovigilance review published in Phytotherapy Research analyzed 198 adverse event reports linked to ashwagandha-containing supplements and identified hepatotoxicity signals, particularly at doses exceeding 600 mg daily or with prolonged use beyond 12 weeks [10]. Without knowing the exact dose in AG1, consumers and clinicians cannot assess this risk.

Proprietary blends are legal under FDA labeling rules. The agency requires that total blend weight be listed but does not require disclosure of individual ingredient amounts within the blend [11]. AG1 discloses amounts for some ingredients (e.g., vitamin C at 467 mg, vitamin D at 50 mcg) but groups others into blends with only aggregate weights. The American Medical Association has formally opposed proprietary blend labeling, noting that it "impedes the ability of healthcare providers to advise patients" [12].

Drug-supplement interactions represent another consideration for multi-ingredient formulas. Vitamin K1 (present in AG1 at 55 mcg per serving) can reduce the anticoagulant effect of warfarin [13]. Ashwagandha may potentiate sedative medications. Milk thistle inhibits CYP3A4 and CYP2C9 enzymes, potentially altering metabolism of statins, immunosuppressants, and oral contraceptives [14]. Any patient on prescription medications should review AG1's full ingredient list with their prescriber. That is not marketing caution. That is standard clinical practice.

Probiotic Viability and Stability Claims

AG1 claims 7.2 billion colony-forming units (CFU) of Lactobacillus acidophilus per serving. The relevant question is viability at the time of consumption, not at the time of manufacture. Probiotics are living organisms. Their survival depends on storage temperature, moisture, pH of the surrounding matrix, and time since production [15].

A 2019 study in Frontiers in Microbiology tested 26 commercial probiotic products and found that 44% contained fewer viable organisms than label claims at the time of testing, with some products showing reductions exceeding 90% [16]. AG1 ships in sealed packets with nitrogen flushing to reduce oxidation, which is a reasonable preservation approach. The brand claims stability through the end of the shelf life but, again, independent verification data are not publicly available.

The International Scientific Association for Probiotics and Prebiotics (ISAPP) recommends that probiotic products disclose CFU counts "at end of shelf life, not at time of manufacture" [17]. Whether AG1's label claim meets this standard is unclear from available public information.

How AG1 Compares to Pharmaceutical-Grade Standards

The term "pharmaceutical grade" has no legal definition in the supplement industry. When clinicians use it informally, they typically mean products manufactured under USP verification or certified through NSF's Dietary Supplement program (distinct from NSF for Sport). AG1 holds neither USP verification nor NSF Dietary Supplement certification. Its NSF for Sport mark covers banned-substance screening, not comprehensive potency and dissolution testing [6].

USP-verified supplements undergo four tiers of evaluation: ingredient identity and potency, contaminant screening (heavy metals, microbes, pesticides), dissolution and bioavailability testing, and ongoing manufacturing audits [18]. The USP standard is voluntary, and very few supplement companies pursue it because of cost and the requirement for full formula disclosure.

Dr. Tod Cooperman, president of ConsumerLab.com, has noted: "Many greens powders fail independent testing for one or more claimed ingredients, or contain contaminant levels that, while legal, exceed what consumers expect from a premium product" [19]. ConsumerLab has not published a public review of AG1's current formula as of May 2026, which itself represents a gap in independent oversight.

Adverse Event Reporting and Post-Market Surveillance

Since 2007, supplement manufacturers have been required to report serious adverse events to the FDA within 15 business days under the Dietary Supplement and Nonprescription Drug Consumer Protection Act [20]. "Serious" is defined as death, life-threatening experience, hospitalization, disability, or congenital anomaly. Mild gastrointestinal symptoms, headaches, or other non-serious effects do not trigger mandatory reporting.

A search of the FDA's Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS) does not reveal a pattern of serious adverse event reports specifically attributed to AG1 as of May 2026 [5]. This is consistent with what would be expected for a greens supplement. It does not constitute evidence of safety in the clinical trial sense. Absence of reported harm is not the same as demonstrated safety through controlled study.

The National Institutes of Health Office of Dietary Supplements maintains a Dietary Supplement Label Database that catalogs label information from products sold in the U.S. [21]. AG1 is listed. The database does not evaluate claims but provides a reference for comparing declared ingredients and doses across similar products.

What Independent Reviews Actually Show

Consumer reviews of AG1 trend positive for taste and convenience. Clinical reviews are more measured. No peer-reviewed randomized controlled trial has evaluated AG1's specific formulation for any health outcome. The brand has funded internal research, but results have not appeared in indexed journals as of this writing.

A 2022 systematic review in Nutrients examined 10 clinical trials of greens powder supplements generally and found "modest evidence" for improvements in markers of oxidative stress but "insufficient evidence" for immune function, energy, or gut health claims [22]. The review noted high heterogeneity across products and small sample sizes (median N = 40) as key limitations.

The distinction between "this product is not proven harmful" and "this product is proven helpful" is the central tension in supplement regulation. AG1 occupies the former category. Its manufacturing standards are above average for the supplement industry. Its evidence base for efficacy claims is thin by pharmaceutical standards. Both of these statements can be true simultaneously.

Patients considering AG1 should calculate whether a $79/month subscription delivers measurable value beyond a $15/month USP-verified multivitamin combined with specific, evidence-based supplements (vitamin D3, omega-3s, magnesium) dosed according to documented deficiencies confirmed by laboratory testing [23].